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LONG-TERM FOLLOW UP OF T CELL DEPLETED TRANSPLANTS FROM
UNRELATED DONORS IN PEDIATRIC PATIENTS
Hale, G.A.1, Krance, R.A.2,3,4, Khan, S.P.2,3, Rochester, R.1,
Horwitz, E.M.1, Turner, V.1, Gee, A.P.2,3,4, Brenner, M.K.2,3,4,
Heslop, H.E.2,3,4 1St Jude Children’s Research Hospital, Memphis, TN;
2Baylor College of Medicine, Houston, TX; 3Texas Children’s Hospital,
Houston, TX; 4The Methodist Hospital, Houston, TX.
Graft-versus-host disease (GVHD) remains a major cause of
mortality and long term morbidity in recipients of hematopoietic
stem cell transplant from unrelated donors. From 1993-2000 we
used partial T cell depletion to reduce this risk and transplanted
116 patients with T cell depleted unrelated donor stem cells on two
successive IRB-approved protocols at St Jude Children’s Research
Hospital (1993-1997 n  75) and Baylor College of Medicine
(1998-2000 n 41). All patients were transplanted for hematologic
malignancy and were stratiﬁed into standard risk (Acute leukemia
or lymphoma in 1st or 2nd remission or CML in 1st chronic phase)
or high risk (Acute leukemia or lymphoma in relapse or  CR3,
CML beyond 1st chronic phase, myelodysplasia or secondary
AML). Patients received marrow from 5/6 or 6/6 matched unre-
lated donors depleted of T cells by incubation with CD6 and CD8
antibodies and baby rabbit complement, which produced a median
T cell depletion of 96%. Conditioning was with Cyclophospha-
mide 45mg/kg x 2, Ara-C 3g/m2 x 6, ATG 30mg/kg x 3 and TBI
1200-1400cGy. In 1997 we reported initial outcome data in the
ﬁrst 51 patients (Hongeng et al Lancet 1997, 350: 767-71 ) with a
2-year disease-free survival estimate for standard-risk recipients of
73	12.1% and for high risk recipients of 32 	 15.1%. We now
report long term follow up on all 116 patients with follow up
ranging between 6.7 and 13.5 years. The 5 and 10 year Kaplan
Meier survival estimate is 60% for 49 standard risk patients and
37% for 67 high risk patients. 4 of the 49 standard risk patients and
26 of the 67 high risk patients relapsed. Three of the patients who
relapsed are long term survivors after relapse ( 10 years) after
donor lymphocyte infusion. All but one relapse occurred within 2
years of transplant. The incidence of grade 3-4 GVHD was 5%
and only 4% of recipients developed extensive chronic GVHD.
The 100 day mortality was 21% in high risk recipients and 19% in
standard risk recipients but the incidence of late non-relapse mor-
tality was low with only two deaths from causes other than relapse
after one year - one death from pulmonary failure at 4.5 years and
one at 10 years in a motor vehicle accident. All long term survivors
have a good performance status. Partial T cell depletion can there-
fore reduce the risk of graft versus host disease and long term
sequelae from this complication without an increased risk of re-
lapse.
IMMUNE RECONSTITUTION
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INSULIN-LIKE GROWTH FACTOR I POSITIVELY REGULATES THYMIC
FUNCTION BY EXPANSION OF THYMOCYTE PRECURSORS AND THYMIC
EPITHELIAL CELLS
Chu, Y.-W.1, Schmitz, S.1, Choudhury, B.1, Gress, R.E.1 1Experimen-
tal Transplantation and Immunology Branch, National Cancer Institute,
Bethesda, MD.
Neuroendocrine growth factors help regulate thymic function
and serve as potential agents to accelerate thymic T-cell produc-
tion following hematopoietic stem cell transplantation (HSCT).
We present evidence supporting insulin-like growth factor I
(IGF-1) as a thymic regulator. Continuous infusion of IGF-1 (100
ug/day) into normal mice resulted in signiﬁcant increases in all
thymocyte populations, including earliest thymocyte precursors
(ETP), with subsequent increases in recent thymic emigrants
(RTE). Time-sequential enumeration of thymic epithelial cell
(TEC) and thymocyte subpopulations and bone marrow and pe-
ripheral LSK (Lineage-, Sca-1, c-kit) precursor populations
showed that expansion of peripheral LSK, occurring on day 4 of
IGF-1 administration, preceded quantitative increases in thymo-
cyte and TEC subpopulations by three days. Concomitant with the
increase in peripheral LSK numbers, cell cycle entry was increased
in bone marrow and peripheral LSK and lineage-CD44 CD25
(DN2) thymocytes. IGF-1 administration also affected TEC turn-
over during this early time period (day 2-7) preceding numeric
increases in TEC. The relative proportions of cortical and med-
ullary TEC were not altered throughout the course of IGF-1
administration. Finally, mice lacking IGF-1 receptor (IGF-1R)
signaling on T-cells were generated through cre-mediated deletion
of the IGF-1R high-afﬁnity binding site (pLCK-cre/loxIGF1R).
Compared to wild-type littermates, pLCK-cre-loxIGF1R mice ex-
hibited a decrease in the number of CD4CD8 thymocytes,
thymic TREC, and splenic naı¨ve T-cells and RTE. IGF-1 treat-
ment, however, restored thymocyte and peripheral subset numbers
in these mice. These results demonstrate: 1) IGF-1 expands thy-
mocyte subpopulations and increases thymic output; 2) IGF-1
expands peripheral thymocyte precursor populations leading to
their increased availability for entry into the thymus; and 3)
IGF-1R signaling is required for the maintenance of normal thy-
mocyte and peripheral T-cell populations, and that presumptive
IGF-1 effects on TEC can overcome the absence of IGF-1R
signaling in thymocytes. Together, the results support the concept
of neuroendocrine growth factors such as IGF-1 in preserving
and/or enhancing thymic function recovery following HSCT, and
suggest that points of regulation in thymic function by IGF-1
include entry of thymocyte precursors into the thymus and the
proportionate expansion of TEC populations that facilitate thymo-
cyte development.
43
A SUBPOPULATION OF HUMAN NK CELLS LACKING INHIBITORY RE-
CEPTORS FOR SELF MHC IS DEVELOPMENTALLY IMMATURE RATHER
THAN AUTOREACTIVE
Cooley, S.A.1, Xiao, F.1, Bergemann, T.L.3, Pitt, M.1, Gleason, M.1,
McCullar, V.1, McQueen, K.2, Guethlein, L.2, Parham, P.2,
Miller, J.S.1 1Division of Hematology, Oncology and Transplantation,
University of Minnesota Cancer Center, Minneapolis, MN; 2Stanford
University, Palo Alto, CA; 3Division of Biostatistics, School of Public
Health, University of Minnesota, Minneapolis, MN.
The effector function of human natural killer (NK) cells is
down-regulated via ligation of inhibitory receptors (killer immu-
noglobulin-like receptors [KIR] and NKG2A) that recognize self
MHC. In order to study the mechanism producing self-tolerance,
which is not yet understood., we developed and validated a quan-
titative, real-time RT-PCR (Q-RT-PCR) assay to measure mRNA
levels from individual NKG2 and KIR genes. Our expression typing
assay accurately predicts genotyping by SSOP (sensitivity 0.94.
speciﬁcity 0.96, PPV 0.97) and gives expression data with a single
quantitative readout. We used this assay to investigate NK cells
circulating in normal blood. We sorted CD56dim NK cells into
KIR and KIR- subsets by ﬂow cytometry using an antibody
cocktail recognizing 6 KIR. Measurements of individual KIR gene
expression showed that not all CD56dim cells express KIR. The
KIR- populations were further divided into NKG2A positive and
negative cells, deﬁning a novel subpopulation of cells committed to
the NK lineage. This KIR- NKG2A- subset comprises 19.4	 2.8%
of CD56dim NK cells in healthy donors, and expresses the acti-
vating NKG2D and NKG2E receptors. Consequently these
CD56
dim
NKG2A-KIR- NK cells do not have ‘at least one’ inhib-
itory receptor for engaging autologous MHC class I. However,
they are not intolerant, autoreactive cells, but instead are imma-
ture, already committed NK cells (based on CD56 expression),
coexpressing CD7, CD16, and CD18. Functional assays showed
this population to be hyporesponsive. Compared to KIR or
NKG2A-expressing subsets, they exhibited impaired degranulation
(measured by CD107a) and poor cytotoxicity against K562 targets.
Furthermore, they produced little IFN- after stimulation with
IL-12 and IL-18, and compared to that of CD56dim NK cells that
express NKG2A, they showed a diminished capacity to proliferate
in response to IL-15. Upon culture on a murine embryonic stromal
cell line with IL-15, these CD56dim NKG2A-KIR- NK cells
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proliferate, express KIR and NKG2A receptors and develop cyto-
toxic and cytokine-producing potential. Umbilical cord blood, a
site of developing hematopoiesis, contained a signiﬁcantly higher
percentage of CD56dim NKG2A-KIR- cells (59 	 11%) support-
ing the notion that these cells are developmentally immature. We
conclude that lineage-committed NK cells in the blood do not
require inhibitory self-tolerance mechanisms until they reach a late
stage of differentiation.
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PRE-CLINICAL STUDY OF THE EFFECT OF THE AS-SIG-TAA/ECDCD40L
VECTOR PRIME-TAA/ECDCD40L PROTEIN BOOST VACCINE IN ELDERLY
RECIPIENTS FOR SUPPRESSION OF RECURRENT CANCER FOLLOWING
ALLOGRAFTING AND DONOR LYMPHOCYTE INFUSIONS (DLI)
Tang, Y.1, Akbulut, H.1, Maynard, J.1, Petersen, L.1, Deisseroth, A.1
1Sidney Kimmel Cancer Center, San Diego, CA.
The mini-allogeneic transplant has opened the door to treat-
ing individuals in the ﬁfth and sixth decades of life. Unfortu-
nately, matched related donors for these individuals usually have
an aged immune system in which the immune response has been
impaired by a reduction in the ratio of antigen naı¨ve/memory
CD4 and CD8 T cells and acquired functional defects in acti-
vated “helper” CD4 T cells (eg diminished CD40 ligand
(CD40L) expression). This has limited the applicability of mini-
allografts to older individuals and to the use of post allograft
vaccines to expand speciﬁc populations of CD8 effector cells to
bolster the anti-cancer and anti-viral immune response. Our
laboratory has developed an adenoviral vector (Ad-sig-TAA/
ecdCD40L) vaccine which is designed for the in vivo target
associated antigen (TAA) loading and activation of dendritic
cells (DCs), and to overcome the absence of CD40L expression
in activated CD4 helper T cells in older individuals. The sub-
cutaneous (sc) injection of this vector leads to the release of a
fusion protein composed of a TAA linked to the extracellular
domain (ecd) of the CD40 ligand (CD40L), which binds to the
CD40 receptor on DCs, activates the DCs, and leads to the
presentation of TAA fragments on Class I MHC. VPP vaccine
overcomes anergy in TAA.Tg transgenic mouse, and induces
TAA speciﬁc memory cells. Two sc injections of the TAA/
ecdCD40L protein as a booster following the sc administration
of the Ad-sig-TAA/ecdCD40L vector (VPP) expands the mag-
nitude of the cellular and humoral immune response induced by
the vector in 18 month old aged mice as well as in younger mice.
This vaccine decreased levels of negative regulatory CD4
FOXP3 T cells in tumor nodules. We administered TBI and an
allogeneic stem cell transplant 7 days post sc injection of the E7
positive TC-1 cells. DLI from an Ad-sig-E7/ecdCD40L vector
prime-E7/ecdCD40L protein boost vaccinated donor were in-
jected iv 3 days post transplant, and a single E7/ecdCD40L
protein boost sc vaccination one week thereafter. We found that
the growth rate of the E7 positive TC-1 tumor cells post
allograft was less in the vaccinated than in the control (injection
of tumor cells followed in 7 days by TBI), or the animals in
which the allograft recipient was vaccinated without DLI. Thus,
the use of DLI from VPP vaccinated allodonor decreased tumor
cell growth post allograft.
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DIRECT ISOLATION AND INFUSION OF DONOR-DERIVED CMV-SPECIFIC
T CELLS FOR TREATMENT OR PROPHYLAXIS OF CMV INFECTION
FOLLOWING ALLOGENEIC TRANSPLANTATION
Lowdell, M.W.1, Thomson, K.1, Julie, A.1, Pang, K.1, Samuel, E.1,
Desborough, M.1, Mackinnon, S.1 1Dept of Haematology, Royal Free &
UCL Med Sch, London, United Kingdom.
Reactivation of CMV is common following allogeneic HSCT
and virus-speciﬁc T lymphocytes are necessary for control.
CMV-speciﬁc donor T cell infusions have been used but most
methods involve several weeks of ex-vivo culture. The current
method involves a 20hr incubation of donor peripheral blood
mononuclear cells with rCMV-pp65 protein. Isolation of inter-
feron-gamma positive T cells by CliniMACS using IFN cap-
ture microbeads (Miltenyi Biotec) provides a CMV-reactive T
cell product which is cryopreserved in dosed aliquots for sub-
sequent infusion. A single arm phase I study is underway, with
CMV-T cells given pre-emptively at ﬁrst detection (by qPCR)
of CMV DNA in peripheral blood, or at day 40-50 as pro-
phylaxis. A dose of 1104 CD3/kg recipient weight is infused
and CMV monitored by weekly PCR. Antiviral drug therapy
commences if the viral load rises above our institutional thresh-
old. 12 patients have received CMV-T cells at a median of 4
weeks post HSCT and 9 are alive and well. None experienced
infusion-related toxicity and no deaths were associated with
CMV-T cell treatment or CMV disease. Incidence and severity
of GvHD was no different from historical controls. The median
yield of CMV-T cells following enrichment was 5.2106 (range
0.29-26.7) of which 24.7% were CD4/IFN and 11.2% were
CD8/IFN; a total mean CMV-reactive cell yield of 2.2
106 per donor. Following infusion, in vivo expansion of
CMV-T cells was seen in all patients. CMV-T cells averaged
9.8% of CD4 cells and 8.1% of CD8 cells by 2-4 weeks
post-infusion; the result of in vivo expansions of CMV-reactive
cells of up to 5000-fold. 9 patients received antiviral therapy for
CMV reactivation but in 5 patients this was required for a
signiﬁcantly shorter period than in historical controls (11-14
days). 3 patients had a second CMV reactivation. 1 patient
showed substantially delayed expansion of CMV-T and required
prolonged anti-viral treatment (33 days). 1 required antiviral
drug treatment, the second received no treatment and cleared
virus after a further in vivo expansion of CMV-T cells, suggest-
ing the presence of a functional memory population. 3 patients
were treated prophylactically at day 40-50 and expansions of
CMV-reactive T cells were seen in all 3 despite lack of detect-
able viral DNA in peripheral blood. This technique rapidly
provides clinical-grade CMV-reactive CD4 and CD8 T cells
which appear to provide effective antiviral immunity.
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THYMIC SHIELDING (TS) IN RECIPIENTS OF TOTAL BODY IRRADIA-
TION (TBI) AND ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL
TRANSPLANT (AD-HSCT): REDUCED RISK OF OPPORTUNISTIC INFEC-
TION IN PATIENTS WITH FANCONI ANEMIA (FA)
MacMillan, M.L.1, Blazar, B.R.1, DeFor, T.E.1, Dusenbery, K.R.1,
Wagner, J.E.1 1University of Minnesota, Minneapolis, MN.
Delayed immune reconstitution and consequent opportunistic
infections remain major obstacles to the successful application
of HSCT, particularly in older patients, those with HLA mis-
matched donors and in selected diseases, such as FA. Based on
preclinical work suggesting that TS may improve immune re-
constitution in recipients of TBI and allogeneic HSCT (J Im-
munol 1987:139:358), we evaluated the safety and potential
efﬁcacy of TS in FA patients. After CT localization of the
thymus, 5HVL cerrubend blocks were fabricated and used to
shield the thymus. Otherwise all patients received the standard
preparative regimen consisting of ﬂudarabine 175 mg/m2, cy-
closphosphamide 40 mg/kg, single fraction TBI 450 cGy, and
antithymocyte globulin, with cyclosporine and short course
methylprednisolone as GVHD immunoprophylaxis. In order to
assess the potential risks and beneﬁts of TS, we compared
transplant outcomes of these FA patients who received TS to FA
patients treated with the exact same preparative regimen with-
out TS. Between April 1999-June 2006, 59 FA patients under-
went AD-HSCT at the University of Minnesota; 16 patients had
TBI with TS and 43 had TBI without TS. For those with and
without TS, donors were HLA matched (n42) or mismatched
(n17), and stem cell sources were T cell depleted bone marrow
(n9 vs n38) or umbilical cord blood (n7 vs n5). While
excess graft failure was considered to be the principal toxicity
risk in recipients of TS, incidence of engraftment was similar in
those with and without TS (94% vs 97% respectively, p.46).
Although not statistically signiﬁcant, survival at one year was
higher in FA patients with TS (67% vs 53% respectively,
p.46). However, as shown, TS was associated with a signiﬁ-
cantly lower risk of all three categories of opportunistic infec-
tion after HSCT (Table 1).
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